1265911-55-4
Chemical Structure
Ticagrelor-d7
- CAS No.: 1265911-55-4
- Formula:C23H21D7F2N6O4S
- Molecular Weight:529.61
IUPAC Name: (1S,2S,3R,5S)-3-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-((propyl-d7)thio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
InChIKey: OEKWJQXRCDYSHL-MHTCSOGVSA-N
SMILES: N(C1=C2C(N(N=N2)[C@@]3(C[C@H](OCCO)[C@@H](O)[C@H]3O)[H])=NC(SC(C(C([2H])([2H])[2H])([2H])[2H])([2H])[2H])=N1)[C@H]4[C@@](C4)(C5=CC(F)=C(F)C=C5)[H]
Biological Activity: Ticagrelor-d7 is the deuterium labeled Ticagrelor. Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ticagrelor-d7 | Ticagrelor-d7 is the deuterium labeled Ticagrelor. Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ticagrelor (Standard) | ≥98% | Ticagrelor (Standard) is the analytical standard of Ticagrelor. This product is intended for research and analytical applications. Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ticagrelor-d4 | Ticagrelor-d4 (AZD6140-d4) is deuterium labeled Ticagrelor. Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ticagrelor | 99.95% | Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Aungraheeta R, et al. Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor. Blood. 2016 Dec 8;128(23):2717-2728. [Content Brief]
